Brainsway Ltd. (TASE:BRIN) has reported successfully completing a 'maintenance trial' (follow-up) for its device on 30 patients suffering from depression at Israel's Shalvata Hospital, who had all previously received preliminary treatment with Brainsway's Deep TMS device.

The patients received five treatments a week over four weeks using Brainsway's Deep TMS device, a unique technology for non-invasive treatment (trans-cranial magnetic stimulation) of clinical depression. The patients subsequently received two treatments weekly over six months and then one treatment per week.

In addition, no side-effects were reported.

The successful trial results lifted Brainsway's share price 6.11% on the TASE today to NIS 9.39, giving a market cap of NIS 378 million.